SeaBridge Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

SeaBridge Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300	Closed	-$6K	–	211
2020 Q3	$6K	Hold	300	–	–	﹤0.01%	242
2020 Q2	$6K	Hold	300	–	–	﹤0.01%	242
2020 Q1	$4K	Hold	300	–	–	﹤0.01%	246
2019 Q4	$4K	Hold	300	–	–	﹤0.01%	246
2019 Q3	$4K	Hold	300	–	–	﹤0.01%	256
2019 Q2	$5K	Hold	300	–	–	﹤0.01%	248
2019 Q1	$5K	Hold	300	–	–	﹤0.01%	242
2018 Q4	$4K	Hold	300	–	–	﹤0.01%	238
2018 Q3	$9K	Hold	300	–	–	﹤0.01%	222
2018 Q2	$8K	Hold	300	–	–	﹤0.01%	232
2018 Q1	$6K	Buy	+300	New	+$7.38K	﹤0.01%	236

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AVAX

Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

SeaBridge Investment Advisors's NTLA Position: Q4 2020 in Review

SeaBridge Investment Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2020, closing a stake of 300 shares — an estimated $6K sold.

SeaBridge Investment Advisors first reported a position in NTLA in Q1 2018 and held it in 11 quarters. The position peaked at $9K in Q3 2018. 240 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

SeaBridge Investment Advisors reported no remaining Intellia Therapeutics position as of Q4 2020 after selling out during the quarter.
SeaBridge Investment Advisors sold 300 Intellia Therapeutics shares in Q4 2020, an estimated $6K.
SeaBridge Investment Advisors first reported a position in Intellia Therapeutics in Q1 2018 and held it in 11 quarters.
SeaBridge Investment Advisors's Intellia Therapeutics position peaked at $9K in Q3 2018.
240 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on SeaBridge Investment Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.